COMPASS Pathways appoints Kabir Nath as chief executive

20 July 2022

UK-based mental health care company COMPASS Pathways (Nasdaq: CMPS) has announced the appointment of Kabir Nath as its chief executive.

COMPASS is developing a new model of psilocybin therapy, in which its proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support.

Most recently serving as senior managing director of global pharmaceuticals at Japanese drugmaker Otsuka Pharmaceutical (TYO: 4578), Mr Nath brings decades of experience in the health care industry to his new role. Prior to this he led the development of pharmaceutical products and digital solutions addressing complex mental health needs as president and CEO of Otsuka’s North America Pharmaceutical Business.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK